Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience
Authors' conclusion
Canakinumab was found to be potentially efficacious and safe in Chinese patients with sJIA.
Study context
- Population
- Chinese children with active systemic juvenile idiopathic arthritis (sJIA) previously treated with tocilizumab7 female and 4 male
- Outcome
- Efficacy of canakinumab
- Follow-up
- 24 weeks
Methodological detailsreal-world data, single-group
- Real-world data
- Single-group
Main finding
As reported in the abstract
- Reduction in number of tender and swollen joints
- P = 0.0059
- Reduction in systemic juvenile arthritis disease activity score
- P < 0.0001
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Corticosteroid discontinuationChildren under corticosteroid treatment | Canakinumab 4 events |
- Corticosteroid discontinuation — Discontinued at week 4
- 1
- Corticosteroid discontinuation — Discontinued at week 12
- 2
- Corticosteroid discontinuation — Discontinued at week 24
- 1
Safety
Adverse events
- Serious adverse events (AEs)
- 0
- Macrophage activation syndrome or death
- 0
- Most common AE was infection
Original publication
Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience. Pediatr Rheumatol Online J. Published 19 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →